on FERMENTALG (EPA:FALG)
Fermentalg announces 17% growth and promising prospects for 2026
Fermentalg achieved a turnover of €13.4 million in 2025, representing a 17% increase compared to the previous year. This result exceeded initial expectations and marks a historic record for the company.
Fermentalg attributes this performance to the expansion of its product portfolio. The company has notably developed innovative BioSolutions such as the EPA/DHA ΩRIGINS™ range and the natural colorant Galdieria Blue™. These advancements allow it to diversify beyond the dietary supplement sector.
The year 2026 looks promising with a target revenue of €20 million. Financial support from its partner Huvepharma is also helping Fermentalg prepare for its future commercial development.
R. H.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all FERMENTALG news